MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. have further bolstered the case for their PI3K-delta inhibitor, zandelisib, with safety and efficacy data from two early-stage studies at the European Hematology Association’s 2022 meeting, including in patients receiving the drug in combination with Roche Holding AG's CD20-directed monoclonal antibody Rituxan (rituximab).
The companies presented updated data on 10 June from a Phase Ib study of zandelisib alone or combined with Rituxan...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?